Bradley McEvoy

2.3k total citations · 1 hit paper
13 papers, 726 citations indexed

About

Bradley McEvoy is a scholar working on Statistics and Probability, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Bradley McEvoy has authored 13 papers receiving a total of 726 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Statistics and Probability, 2 papers in Molecular Biology and 2 papers in Cellular and Molecular Neuroscience. Recurrent topics in Bradley McEvoy's work include Statistical Methods in Clinical Trials (3 papers), Schizophrenia research and treatment (2 papers) and Pharmacological Effects of Natural Compounds (2 papers). Bradley McEvoy is often cited by papers focused on Statistical Methods in Clinical Trials (3 papers), Schizophrenia research and treatment (2 papers) and Pharmacological Effects of Natural Compounds (2 papers). Bradley McEvoy collaborates with scholars based in United States, United Kingdom and Australia. Bradley McEvoy's co-authors include Brenda F. Baker, Steven G. Hughes, Richard S. Geary, Nguyen C. Pham, Joseph L. Witztum, Mark J. Graham, Wuxia Fu, Andrés Digenio, Eunju Hurh and Teresa Brandt and has published in prestigious journals such as New England Journal of Medicine, Neurology and PEDIATRICS.

In The Last Decade

Bradley McEvoy

12 papers receiving 715 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

2017 454 citations Mark J. Graham, Richard Lee et al. New England Journal of Medicine profile →

Peers

Bradley McEvoy

CCM

EDM

MB

SURGE

CR

Isamu Fukamachi Japan

D. Scherer Germany

Carole Amant France

Frank Leijten Netherlands

Xavier Hermant France

Hajime Nakaoka Japan

Mikihiko Kawano Japan

Andrew K. Gormley United States

Sebastian A. Potthoff Germany

Ayumi Ide Japan

Isamu Fukamachi Japan

Bradley McEvoy

270 ×0.9

CCM

377 ×1.7

EDM

167 ×0.8

MB

282 ×1.4

SURGE

100 ×0.7

CR

Citations per year, relative to Bradley McEvoy Bradley McEvoy (= 1×) peers Isamu Fukamachi

Countries citing papers authored by Bradley McEvoy

Since Specialization

Citations

This map shows the geographic impact of Bradley McEvoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bradley McEvoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bradley McEvoy more than expected).

Fields of papers citing papers by Bradley McEvoy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bradley McEvoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bradley McEvoy. The network helps show where Bradley McEvoy may publish in the future.

Co-authorship network of co-authors of Bradley McEvoy

This figure shows the co-authorship network connecting the top 25 collaborators of Bradley McEvoy. A scholar is included among the top collaborators of Bradley McEvoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bradley McEvoy. Bradley McEvoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

Hamel, Johanna, Payam Soltanzadeh, Charles A. Thornton, et al.. (2026). An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1. New England Journal of Medicine. 394(8). 763–772.

2.

Johnson, Nicholas, John Day, Johanna Hamel, et al.. (2023). Preliminary Assessment of the Phase 1/2 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Patients with Myotonic Dystrophy Type 1 (DM1) (MARINA) (S48.002). Neurology. 100(17_supplement_2). 2 indexed citations

3.

Ballard, Clive, Erin P. Foff, Pierre N. Tariot, et al.. (2021). Impact of pimavanserin on cognitive measures in patients with neurodegenerative disease (NDD): results from 4 placebo-controlled clinical studies (2369). Neurology. 96(15_supplement). 1 indexed citations

4.

Cummings, Jeffrey L., Zahinoor Ismail, Bradford C. Dickerson, et al.. (2021). Development and assessment of a brief screening tool for psychosis in dementia. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 13(1). e12254–e12254. 2 indexed citations

5.

Tariot, Pierre N., Jeffrey L. Cummings, Maria Soto‐Martin, et al.. (2021). Trial of Pimavanserin in Dementia-Related Psychosis. New England Journal of Medicine. 385(4). 309–319. 77 indexed citations

6.

Foff, Erin P., et al.. (2020). 427 - HARMONY study: pimavanserin significantly reduces risk of relapse of dementia-related psychosis. International Psychogeriatrics. 32. 143–143. 3 indexed citations

7.

Tariot, Pierre N., et al.. (2020). HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis. Innovation in Aging. 4(Supplement_1). 163–164. 2 indexed citations

8.

Crooke, Stanley T., Brenda F. Baker, Joseph L. Witztum, et al.. (2017). The Effects of 2′- O -Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials. Nucleic Acid Therapeutics. 27(3). 121–129. 100 indexed citations

9.

Graham, Mark J., Richard Lee, Teresa Brandt, et al.. (2017). Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. New England Journal of Medicine. 377(3). 222–232. 454 indexed citations breakdown →

10.

McEvoy, Bradley. (2015). Missing data in clinical trials for weight management. Journal of Biopharmaceutical Statistics. 26(1). 30–36. 19 indexed citations

11.

McEvoy, Bradley, Rajesh Nandy, & Ram C. Tiwari. (2013). Bayesian Approach for Clinical Trial Safety Data Using an Ising Prior. Biometrics. 69(3). 661–672. 4 indexed citations

12.

McEvoy, Bradley, et al.. (2013). Testing A Noninferiority Hypothesis: What to Anticipate when the Adverse Event is Rare. Journal of Biopharmaceutical Statistics. 23(1). 122–128. 2 indexed citations

13.

McMahon, Ann, Mark Levenson, Bradley McEvoy, Andrew D. Mosholder, & Dianne Murphy. (2011). Age and Risks of FDA-Approved Long-Acting β2-Adrenergic Receptor Agonists. PEDIATRICS. 128(5). e1147–e1154. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact